Key result
Bedtime antihypertensives show no benefit over morning dosing for major cardiovascular events.
Why the study?
Antihypertensive medications are traditionally taken in the morning, but recent studies suggested bedtime dosing might be more effective in reducing cardiovascular risk.
Does bedtime administration of antihypertensive medication reduce major adverse cardiovascular events compared to morning administration?
Meta-Analysis (n=46,477)
Does bedtime administration of antihypertensive medication reduce major adverse cardiovascular events compared to morning administration?
This meta-analysis demonstrates that bedtime administration of antihypertensive medications does not significantly reduce cardiovascular events compared to morning administration.
Answers are grounded in this paper and cite their sources.
Bedtime antihypertensives confer no MACE advantage over morning dosing; reinforces consensus against chronotherapy benefit.
BACKGROUND Antihypertensive medications are essential for preventing cardiovascular events and have traditionally been taken in the morning. However, recent studies have suggested that taking the medication at bedtime may be more effective in reducing cardiovascular risk. This study aimed to examine the association between dosing time and cardiovascular outcomes. METHODS Randomized controlled trials were retrieved through a systematic literature review using PubMed and Embase. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of all-cause (or cardiovascular) death, myocardial infarction, stroke, and hospitalization for heart failure. Secondary outcomes included each component of the primary outcome. A random-effects model was applied to calculate the pooled hazard ratio (HR) for each outcome. RESULTS Five randomized controlled trials with 46,477 participants (bedtime, 23,178; morning, 23,299) were included. The median follow-up period ranged from 1.1 to 6.3 years, and the mean or median age ranged from 55.6 to 88 years. We found no evidence that bedtime antihypertensives administration was associated with the risk of MACE [HR = 0.71; 95% confidence interval (CI), 0.43-1.16], all-cause death (HR = 0.76; 95% CI, 0.49-1.17), stroke (HR = 0.70; 95% CI, 0.39-1.23), myocardial infarction (HR = 0.88; 95% CI, 0.56-1.38), or hospitalization for heart failure (HR = 0.58; 95% CI, 0.26-1.33), compared to morning administration. CONCLUSIONS Administration of antihypertensives at bedtime was not significantly associated with a lower incidence of cardiovascular outcomes in comparison with administration in the morning.
No takes yet. Share an insight, caveat, or question.
Hiruma et al. (2026) conducted a meta-analysis in Hypertension (n=46,477). Bedtime antihypertensive administration vs. Morning antihypertensive administration was evaluated on Major adverse cardiovascular events (MACE), defined as a composite of all-cause (or cardiovascular) death, myocardial infarction, stroke, and hospitalization for heart failure (HR 0.71, 95% CI 0.43-1.16). Bedtime administration of antihypertensives was not associated with a lower risk of major cardiovascular events compared to morning administration.
Synapse has enriched 10 related papers. Consider them for comparative context: